Methyl 6-benzyl-3-hydroxy-3,6-dimethyl-1,2-dioxane-4-carboxylate.

Alexandre Benech 1, Omar Khoumeri 1, Christophe Curti 1,2,* Patrice Vanelle 1,2,*

1 Aix Marseille University, CNRS, ICR UMR 7273, Team Pharmaco-Chimie Radicalaire, Faculty of Pharmacy, 27 Boulevard Jean Moulin, CS30064, CEDEX 05, 13385 Marseille, France
2 Central Service for Pharmaceutical Quality and Information SCQIP, Pharmacy Department, Hospital Conception, AP-HM, 13005 Marseille, France
*Correspondence: christophe.curti@univ-amu.fr (C.C.); patrice.vanelle@univ-amu.fr (P.V.)

Supplementary materials
Figure S1. $^1$H NMR (400 MHz, CDCl$_3$) complete spectrum of the new compound 1.
Figure S2. $^1$H COSY NMR (400 MHz, CDCl$_3$) spectrum of the new compound 1
Figure S3. $^1$H NMR (400 MHz, CDCl$_3$) spectrum of the diastereoisomer 1
Figure S4. $^1$H NMR (400 MHz, CDCl$_3$) spectrum of the diastereoisomer 1'.
Figure S5. $^{13}$C NMR (101 MHz, CDCl$_3$) complete spectrum of the new compound 1
Figure S6. $^{13}$C NMR (101 MHz, CDCl$_3$) spectrum of the diastereoisomer 1
Figure S7. $^{13}$C NMR (101 MHz, CDCl$_3$) spectrum of the diastereoisomer 1'
Figure S8. $^{13}$C DEPT NMR (101 MHz, CDCl$_3$) spectrum of the new compound 1